

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

22. (Original) A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment

(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and

(b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.

23. (Original) A method of claim 22 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate or a pharmaceutically acceptable salt of said GABA agonist.

24. (Original) A method of claim 23 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin or a pharmaceutically acceptable salt of said GABA agonist.

25. (Original) A method of claim 24 wherein said GABA agonist is pregabalin or a pharmaceutically acceptable salt thereof.

26. (Original) A method of claim 24 wherein said GABA agonist is gabapentin or a pharmaceutically acceptable salt thereof.

27. (Original) A method of claim 22 wherein said aldose reductase inhibitor is fidarestat, epalrestat, minalrestat, SPR-210, zenarestat, zopolrestat or a pharmaceutically acceptable salt of said aldose reductase inhibitor.

28. (Original) A method of claim 22 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.

29. (Original) A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment a pharmaceutical composition comprising

(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and

(b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI.

30. (Original) A method of claim 29 wherein said pharmaceutical composition additionally comprises a pharmaceutically acceptable vehicle, carrier or diluent.

31. (Original) A method of claim 29 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.

32. (Reinstated – formerly claim 1) A pharmaceutical composition comprising:

- a. an amount of a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug; and
- b. an amount of an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug.

33. (Reinstated – formerly claim 2) A pharmaceutical composition of claim 32 additionally comprising a pharmaceutically acceptable vehicle, carrier or diluent.

34. (Reinstated – formerly claim 3) A pharmaceutical composition of claim 33 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug.

35. (Reinstated – formerly claim 4) A pharmaceutical composition of claim 34 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug.

36. (Reinstated – formerly claim 5) A pharmaceutical composition of claim 35 wherein said GABA agonist is pregabalin, a prodrug thereof or a pharmaceutically acceptable salt of said pregabalin or said prodrug.

37. (Reinstated – formerly claim 6) A pharmaceutical composition of claim 35 wherein said GABA agonist is gabapentin, a prodrug thereof or a pharmaceutically acceptable salt of said gabapentin or said prodrug.

38. (Reinstated – formerly claim 7) A pharmaceutical composition of claim 33 wherein said ARI is fidarestat, epalrestat, minalrestat, SPR-210, zenarastat,

zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug.

39. (Reinstated – formerly claim 8) A pharmaceutical composition of claim 38 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabin, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug.

40. (Reinstated – formerly claim 9) A pharmaceutical composition of claim 39 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate and pregabalin, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug.

41. (Reinstated – formerly claim 10) A pharmaceutical composition of claim 40 wherein said GABA agonist is pregabalin, a prodrug thereof or a pharmaceutically acceptable salt of said pregabalin or said prodrug.

42. (Reinstated – formerly claim 11) A pharmaceutical composition of claim 40 wherein said GABA agonist is gabapentin, a prodrug thereof or a pharmaceutically acceptable salt of said gabapentin or said prodrug.

43. (Reinstated – formerly claim 12) A kit for achieving a therapeutic effect in a mammal comprising:

a. an amount of a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug and a pharmaceutically acceptable vehicle, carrier or diluent in a first unit dosage form;

b. an amount of an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a pharmaceutically acceptable vehicle, carrier or diluent in a second unit dosage form; and

c. a container.

44. (Reinstated – formerly claim 13) A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal

(a) an amount of a first compound, said first compound being a GABA agonist, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug; and

(b) an amount of a second compound, said second compound being an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug;

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.

45. (Reinstated – formerly claim 14) A method of claim 44 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug.

B₁
46. (Reinstated – formerly claim 15) A method of claim 45 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin, a prodrug thereof or a pharmaceutically acceptable salt of said GABA agonist or said prodrug.

47. (Reinstated – formerly claim 16) A method of claim 46 wherein said GABA agonist is pregabalin, a prodrug thereof or a pharmaceutically acceptable salt of said pregabalin or said prodrug.

48. (Reinstated – formerly claim 17) A method of claim 46 wherein said GABA agonist is gabapentin, a prodrug thereof or a pharmaceutically acceptable salt of said gabapentin or said prodrug.
